The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-in-human phase I study of BVAC-B cell therapy in HER2-positive advanced gastric cancer.
 
Jii Bum Lee
No Relationships to Disclose
 
Woo Sun Kwon
No Relationships to Disclose
 
Hyo Song Kim
No Relationships to Disclose
 
Minkyu Jung
Honoraria - Celltrion; Lilly
 
Sinyoung Kim
No Relationships to Disclose
 
Myunghwan Park
Employment - Cellid
 
Wuhyun Kim
Employment - Cellid
Stock and Other Ownership Interests - Cellid
 
Ki-Young Choi
Employment - Cellid
Stock and Other Ownership Interests - Cellid
 
Taegwon Oh
Employment - Cellid
Leadership - Cellid
Stock and Other Ownership Interests - Cellid
 
Chang-Yuil Kang
Leadership - Cellid
Stock and Other Ownership Interests - Cellid
Consulting or Advisory Role - SL Bigen
 
Hyun Cheol Chung
Consulting or Advisory Role - Amgen; Beigene; Bristol-Myers Squibb; Celltrion; Gloria Biosciences; Lilly; Merck Serono; MSD; Quintiles; Taiho Pharmaceutical; Zymeworks
Speakers' Bureau - Foundation medicine; Lilly; Merck Serono
Research Funding - Amgen; Beigene; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Merck Serono; MSD; Taiho Pharmaceutical
 
Sun Young Rha
Consulting or Advisory Role - Abbvie; Daiichi Sankyo; Eisai; Ipsen; MSD Oncology; Novartis
Speakers' Bureau - Ipsen; Lilly
Research Funding - ASLAN Pharmaceuticals; Bayer; Bristol-Myers Squibb; Cellid; Eisai; Immunome; medpacto; MSD Oncology; Roche/Genentech; Sillajen